130 related articles for article (PubMed ID: 38469902)
21. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.
Shen X; Yuan Z; Mei J; Zhang Z; Guo J; Wu Z; Wu J; Zhang H; Pan J; Huang W; Gong H; Yuan D; Xiao P; Wang Y; Shuai Y; Lin S; Pan Q; Zhou T; Watkins PB; Wu F
Drug Saf; 2014 Jan; 37(1):43-51. PubMed ID: 24203912
[TBL] [Abstract][Full Text] [Related]
22. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
[TBL] [Abstract][Full Text] [Related]
23. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system.
Ulcickas Yood M; Bortolini M; Casso D; Beck JG; Oliveria SA; Wells KE; Woodcroft KJ; Wang LI
Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):427-34. PubMed ID: 25683797
[TBL] [Abstract][Full Text] [Related]
24. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial.
Morrow AJ; Ford TJ; Mangion K; Kotecha T; Rakhit R; Galasko G; Hoole S; Davenport A; Kharbanda R; Ferreira VM; Shanmuganathan M; Chiribiri A; Perera D; Rahman H; Arnold JR; Greenwood JP; Fisher M; Husmeier D; Hill NA; Luo X; Williams N; Miller L; Dempster J; Macfarlane PW; Welsh P; Sattar N; Whittaker A; Connachie AM; Padmanabhan S; Berry C
Am Heart J; 2020 Nov; 229():70-80. PubMed ID: 32942043
[TBL] [Abstract][Full Text] [Related]
26. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Watkins PB; Dube LM; Walton-Bowen K; Cameron CM; Kasten LE
Drug Saf; 2007; 30(9):805-15. PubMed ID: 17722971
[TBL] [Abstract][Full Text] [Related]
27. The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
Veenit V; Heerspink HJL; Ahlström C; Greasley PJ; Skritic S; van Zuydam N; Kohan DE; Hansen PBL; Menzies RI
Nephrol Dial Transplant; 2023 Sep; 38(10):2289-2297. PubMed ID: 37102226
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment data is highly predictive of liver chemistry signals in clinical trials.
Cai Z; Bresell A; Steinberg MH; Silberg DG; Furlong ST
Drug Des Devel Ther; 2012; 6():359-69. PubMed ID: 23226004
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
[TBL] [Abstract][Full Text] [Related]
30. Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial.
Patel KR; Blair CJ; Tislow JD
Pulm Circ; 2018; 8(4):2045894018797273. PubMed ID: 30124136
[TBL] [Abstract][Full Text] [Related]
31. The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects.
Mansfield AS; Rudek MA; Vulih D; Smith GL; Harris PJ; Ivy SP;
Clin Cancer Res; 2016 Nov; 22(22):5472-5479. PubMed ID: 27189163
[TBL] [Abstract][Full Text] [Related]
32. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Genovese MC; Kremer JM; van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Dimonaco S; Brockwell L
Arthritis Rheumatol; 2017 Sep; 69(9):1751-1761. PubMed ID: 28597609
[TBL] [Abstract][Full Text] [Related]
33. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
Lewis JH; Gelderblom H; van de Sande M; Stacchiotti S; Healey JH; Tap WD; Wagner AJ; Pousa AL; Druta M; Lin CC; Baba HA; Choi Y; Wang Q; Shuster DE; Bauer S
Oncologist; 2021 May; 26(5):e863-e873. PubMed ID: 33289960
[TBL] [Abstract][Full Text] [Related]
34. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer.
Ranson M; Wilson RH; O'Sullivan JM; Maruoka M; Yamaguchi A; Cowan RA; Logue JP; Tomkinson H; Tominaga N; Swaisland H; Oliver S; Usami M
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):708-17. PubMed ID: 20979929
[TBL] [Abstract][Full Text] [Related]
36. Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.
Clarkson-Jones JA; Kenyon AS; Kemp J; Lenz EM; Oliver SD; Swaisland H
Xenobiotica; 2012 Apr; 42(4):363-71. PubMed ID: 22014279
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis.
Wu Y; Shao N; Shen ZX; Li Q; Wang Y; Li C; Ma G; Dong J; Lu XJ; Feng NH
Eur Rev Med Pharmacol Sci; 2014; 18(21):3291-6. PubMed ID: 25487941
[TBL] [Abstract][Full Text] [Related]
38. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring.
Shamseddeen H; Vilar-Gomez E; Chalasani N; Myers RP; Subramanian GM; Shlevin HH; Allgood AE; Orman ES
Drug Saf; 2020 Mar; 43(3):281-290. PubMed ID: 31907854
[TBL] [Abstract][Full Text] [Related]
39. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.
Perlemuter G; Cacoub P; Valla D; Guyader D; Saba B; Batailler C; Moore K
CNS Drugs; 2016 Sep; 30(9):877-88. PubMed ID: 27342740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
